Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.

TTV and NTV measured on pretreatment FDG PET/CT are significant prognosis factor for stage III-IV NSCLC treated by pembrolizumab and TTV could have a higher prognostic value than MTV.